Cel-Sci Corporation
$1.66
$0.17 (+11.41%)
$1.51Day Range$1.70
Key Statistics
Market Cap
$26.21M
Shares Outstanding
17.6M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Dec 8, 1983
Round Lot
100
Locale
US
Trading Data
Day Open
$1.53
Day High
$1.70
Day Low
$1.51
Volume
270.3K
VWAP
$1.62
Prev Close
$1.49
Transactions
--
Acc. Volume
--
About Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283644 employees8229 BOONE BLVD ., VIENNA, VA, 22182(703) 506-9460IPO Dec 8, 1983US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000725363
- Composite FIGI
- BBG000H5G6L5
- Share Class FIGI
- BBG001SBRBG1
- Ticker Root
- CVM
- SIC Code
- 2836
About Cel-Sci Corporation (CVM) Stock
Cel-Sci Corporation (CVM) closed the 2026-09-18 session at $1.66, up 11.41% versus the previous close (+0.17). The stock opened at $1.53 and traded between $1.51 and $1.70 during that session. Session trading volume was 270K shares. The volume-weighted average price (VWAP) is $1.62.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Cel-Sci Corporation has a market capitalization of $26.2 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CVM is listed on the XASE exchange. The company employs approximately 44 people. Cel-Sci Corporation is headquartered in VIENNA, VA. The recorded listing date is 1983-12-08.
On this page you can find market CVM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.